A Mycobacterium tuberculosis (H37Rv)-infected guinea pig model was used to screen for targeted delivery to the lungs by insufflation (with lactose excipient) or nebulization, of either rifampicin alone, rifampicin within poly(lactide-co-glycolide) microspheres (R-PLGA) or polymer microparticles alone (PLGA). Animals treated with single and double doses of R-PLGA microspheres exhibited significantly reduced numbers of viable bacteria, inflammation and lung damage compared with lactose-, PLGA- or rifampicin-treated animals 28 days post-infection (P < 0.05). Two doses of R-PLGA resulted in reduced splenic enlargement. These studies support the potential of R-PLGA delivered to the lung to treat pulmonary tuberculosis
Airways delivery of rifampicin microparticles for the treatment of tuberculosis
Suarez, S., O'Hara, P., Kazantseva, M., Newcomer, CE., Hopfer, R., McMurray, DN., & Hickey, A. (2001). Airways delivery of rifampicin microparticles for the treatment of tuberculosis. Journal of Antimicrobial Chemotherapy, 48(3), 431-434. https://doi.org/10.1093/jac/48.3.431
Abstract
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Meet the Experts
View All ExpertsRecent Publications
Article
Use of a web-based portal to return normal individual research results in Early Check
Article
Personal exposure to PM2.5 in different microenvironments and activities for retired adults in two megacities, China
Article
Estimating global artisanal fishing fleet responses in an era of rapid climate and economic change
Article